Analysts expect GenMark Diagnostics, Inc (NASDAQ:GNMK) to post earnings of ($0.21) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for GenMark Diagnostics’ earnings. The lowest EPS estimate is ($0.22) and the highest is ($0.20). GenMark Diagnostics reported earnings of ($0.30) per share during the same quarter last year, which indicates a positive year over year growth rate of 30%. The business is scheduled to announce its next quarterly earnings report on Monday, July 29th.

According to Zacks, analysts expect that GenMark Diagnostics will report full year earnings of ($0.81) per share for the current year, with EPS estimates ranging from ($0.85) to ($0.74). For the next financial year, analysts forecast that the firm will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.61) to ($0.38). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow GenMark Diagnostics.

GenMark Diagnostics (NASDAQ:GNMK) last issued its earnings results on Tuesday, April 30th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $21.53 million during the quarter, compared to the consensus estimate of $21.08 million. GenMark Diagnostics had a negative net margin of 71.40% and a negative return on equity of 137.04%.

GNMK has been the topic of several recent analyst reports. BidaskClub raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday, February 23rd. Zacks Investment Research lowered shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 12th. Needham & Company LLC reissued a “buy” rating and set a $12.00 price objective on shares of GenMark Diagnostics in a research note on Friday, February 22nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $10.00 price target on shares of GenMark Diagnostics in a research note on Wednesday, May 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. GenMark Diagnostics currently has an average rating of “Hold” and an average price target of $9.67.

Shares of NASDAQ GNMK opened at $7.25 on Wednesday. GenMark Diagnostics has a 1 year low of $3.58 and a 1 year high of $8.81. The stock has a market capitalization of $404.33 million, a PE ratio of -7.97 and a beta of 1.55. The company has a debt-to-equity ratio of 1.96, a quick ratio of 3.40 and a current ratio of 3.93.

In other GenMark Diagnostics news, SVP Eric Stier sold 11,243 shares of GenMark Diagnostics stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $6.80, for a total value of $76,452.40. Following the transaction, the senior vice president now owns 241,754 shares of the company’s stock, valued at $1,643,927.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Hany Massarany sold 5,562 shares of GenMark Diagnostics stock in a transaction that occurred on Wednesday, February 20th. The shares were sold at an average price of $6.16, for a total transaction of $34,261.92. Following the completion of the transaction, the insider now directly owns 909,562 shares in the company, valued at approximately $5,602,901.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 140,153 shares of company stock worth $996,548. Insiders own 5.24% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. increased its holdings in GenMark Diagnostics by 7.5% during the third quarter. BlackRock Inc. now owns 3,609,795 shares of the medical equipment provider’s stock worth $26,532,000 after buying an additional 251,078 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of GenMark Diagnostics by 0.8% in the third quarter. JPMorgan Chase & Co. now owns 4,414,814 shares of the medical equipment provider’s stock valued at $32,448,000 after acquiring an additional 36,100 shares during the period. MetLife Investment Advisors LLC boosted its position in shares of GenMark Diagnostics by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 40,896 shares of the medical equipment provider’s stock valued at $301,000 after acquiring an additional 14,546 shares during the period. Vanguard Group Inc. boosted its position in shares of GenMark Diagnostics by 1.4% in the third quarter. Vanguard Group Inc. now owns 2,613,213 shares of the medical equipment provider’s stock valued at $19,207,000 after acquiring an additional 34,940 shares during the period. Finally, Vanguard Group Inc boosted its position in shares of GenMark Diagnostics by 1.4% in the third quarter. Vanguard Group Inc now owns 2,613,213 shares of the medical equipment provider’s stock valued at $19,207,000 after acquiring an additional 34,940 shares during the period. 90.77% of the stock is currently owned by hedge funds and other institutional investors.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Further Reading: Oversold

Get a free copy of the Zacks research report on GenMark Diagnostics (GNMK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.